PSMA-RADS 2.0版在前列腺癌患者肺转移评估中的价值及PSMA PET/CT参数对鉴别诊断效率的提升
回顾性分析2016年10月至2023年7月接受Al18F-PSMA-BCH PET/CT的96例前列腺癌伴肺部阴影患者共148个病灶。SUVmax与边缘光滑是肺转移的独立预测因子,两者并联试验AUC为0.86(95%CI:0.79,0.94;P<0.001)。PSMA-RADS 2至5分的并联试验诊断准确率分别为85.7%、79.6%、100%、92.9%。
要点
- 148个肺部病灶中肺转移80个(54.1%)、肺癌20个(13.5%)、良性48个(32.4%)。
- SUVmax与边缘光滑均为肺转移独立预测因子(均P<0.05)。
- 两参数并联试验AUC 0.86(95%CI:0.79,0.94;P<0.001)。
核心结论
- Al18F-PSMA-BCH PET/CT参数有助于鉴别前列腺癌患者的肺转移,与PSMA-RADS 2.0版整合时提供增量价值。
研究设计与样本
- 回顾性分析2016年10月至2023年7月接受Al18F-PSMA-BCH PET/CT的96例前列腺癌伴肺部阴影(含肺转移、肺癌、肺部良性阴影)患者,共148个肺部病灶。
主要发现
- 148个肺部病灶中良性48个(32.4%)、肺癌20个(13.5%)、肺转移80个(54.1%)。
- PSMA-RADS评分2至5分的病灶数分别为8个(5.4%)、88个(59.5%)、7个(4.7%)、45个(30.4%)。
- SUVmax与边缘光滑均为肺转移的独立预测因子(均P<0.05)。
- 两参数并联试验鉴别肺转移的AUC为0.86(95%CI:0.79,0.94;P<0.001)。
- 并联试验在PSMA-RADS评分2至5分时的诊断准确率分别为85.7%、79.6%、100%、92.9%。
关键数值与推荐
- PSMA-RADS 2.0版评分2至5分对应的病灶数依次为8个(5.4%)、88个(59.5%)、7个(4.7%)、45个(30.4%)。
- 两参数并联试验AUC 0.86(95%CI:0.79,0.94;P<0.001)。
- 并联试验在PSMA-RADS 2至5分的诊断准确率分别为85.7%、79.6%、100%、92.9%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was to investigate the application of PSMA-RADS version 2.0 in assessment of pulmonary metastases in patients with prostate cancer and whether PSMA PET/CT parameters provide incremental value. PATIENTS AND METHODS: From October 2016 to July 2023, PC patients with pulmonary opacities (including pulmonary metastases, lung cancer, and pulmonary benign opacities) who underwent Al 18 F-PSMA-BCH PET/CT scans were retrospectively analyzed. CT imaging characteristics, including the longest diameter, density, smoothness, lobulation, pleural retraction, and vacuole sign, as well as PET parameters including SUV max and tumor-to-background ratio, were measured and analyzed. Additionally, the pulmonary PSMA-RADS score for each patient was determined. Independent predictors of pulmonary metastases were identified through univariate analysis and multivariate logistic regression analysis, which were utilized to construct a parallel diagnostic test. The differential diagnostic performances were evaluated using receiver operating characteristic analysis. RESULTS: A total of 148 pulmonary opacities from 96 patients were retrospectively included. The number of pulmonary benign opacities, lung cancer, and pulmonary metastases were 48 (32.4%), 20 (13.5%), and 80 (54.1%), respectively. The number of opacities across different PSMA-RADS scores from 2 to 5 was 8 (5.4%), 88 (59.5%), 7 (4.7%), and 45 (30.4%). SUV max and smooth edges were independent predictors of pulmonary metastases (both P < 0.05), and the AUC of the parallel test for these 2 parameters was 0.86 (95% confidence interval: 0.79, 0.94; P < 0.001). Furthermore, the diagnostic accuracy of the parallel test across PSMA-RADS score from 2 to 5 was 85.7%, 79.6%, 100%, and 92.9%, respectively. CONCLUSIONS: Al 18 F-PSMA-BCH PET/CT parameters were helpful in differentiating pulmonary metastases in PC patients and provided incremental value when integrated with PSMA-RADS version 2.0.
引用
- Cui Y, Zhou X, Song Y, et al. The Value of PSMA-RADS Version 2.0 in the Assessment of Pulmonary Metastases in Patients With Prostate Cancer and the Improvement of Differential Diagnosis Efficiency by PSMA PET/CT Parameters. Clin Nucl Med. 2024. PMID: 39192508. doi:10.1097/RLU.0000000000005409
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。